“LLonger therapy with fibrates in type 2 diabetics does not reduce Major coronary events but reduces total cardiovascular events” (2006) Portuguese Journal of Family Medicine and General Practice, 22(3), pp. 401–2. doi:10.32385/rpmgf.v22i3.10257.